Regen BioPharma to Present at Emerging Growth Conference on May 9, 2024

Regen BioPharma, Inc., a biotechnology firm, is set to present at the Emerging Growth Conference on May 9, 2024. This event, designed for individual and institutional investors as well as advisors and analysts, will offer a real-time, interactive presentation from the company. Attendees will have the opportunity to engage directly with Regen BioPharma's CEO, Dr. David Koos, during the session. Dr. Koos and his team aim to respond to as many questions as possible from the participants.

At this conference, Regen BioPharma will update stakeholders on their clinical and preclinical programs, specifically highlighting their Phase 1 clinical study-ready HemaXellerate and preclinical DuraCAR projects. These updates are intended to provide a deeper insight into the company’s ongoing efforts in the biotechnology space.

Regen BioPharma's presentation is scheduled for 1:45 - 2:15 PM Eastern Time on May 9, 2024. Attendees are encouraged to register beforehand to secure their participation and to receive any pertinent updates. For those unable to join the live event, a recorded webcast will be accessible on EmergingGrowth.com.

The Emerging Growth Conference is a platform designed to facilitate communication between public companies and the investment community. It allows companies to present new products, services, and significant announcements efficiently. This conference attracts a broad audience, including individual and institutional investors, investment advisors, and analysts, and focuses on companies with strong management, innovative products, and long-term growth potential.

Regen BioPharma, Inc., traded under the ticker symbols RGBP and RGBPP, is a biotechnology company dedicated to advancing novel technologies in immunology and immunotherapy. The company is actively working on mRNA and small molecule therapies aimed at treating cancer and autoimmune disorders. Their goal is to swiftly move these technologies through pre-clinical and Phase I/II clinical trials.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!